Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Mar;85(3):273-6.
doi: 10.1038/clpt.2008.213. Epub 2008 Nov 12.

Interindividual Variation in the Pharmacokinetics of Delta9-tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

Affiliations
Comparative Study

Interindividual Variation in the Pharmacokinetics of Delta9-tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

C Sachse-Seeboth et al. Clin Pharmacol Ther. .

Abstract

The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback